Quantcast
Home > Quotes > CRTX

Cortexyme, Inc. Common Stock (CRTX) Quote & Summary Data

CRTX 
$54.6
*  
2.40
4.21%
Get CRTX Alerts
*Delayed - data as of Jan. 27, 2020  -  Find a broker to begin trading CRTX now
Exchange:NASDAQ
Industry: Health Care
View:    CRTX Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
42
Today's High / Low
$ 58.8515 / $ 53.853
Share Volume
118,666
50 Day Avg. Daily Volume
222,645
Previous Close
$ 57
52 Week High / Low
$ 72.94 / $ 19.35
Market Cap
1,466,145,572
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1

Intraday Chart

Shares Traded

Share Volume:
118,666
50 Day Avg. Daily Volume:
222,645

Trading Range

The current last sale of $54.60 is 182.17% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 58.8515 $ 72.94
 Low: $ 53.853 $ 19.35

ETFs with CRTX as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
1.5% Virtus LifeSci Biotech Clinical Trials ETF (BBC) +10.46 (40.41%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer's and other degenerative diseases. Our approach is based on the seminal discovery of the presence of Porphyromonas gingivalis, or P. gingivalis, and its secreted toxic virulence factor proteases, called gingipains, in the brains of greater than 90% of more than 100 Alzheimer's patients observed across multiple studies to date. Additionally, we have observed that P. gingivalis infection causes Alzheimer's pathology in animal models, and these effects have been successfully treated with a gingipain inhibitor in preclinical studies. Our proprietary lead drug candidate, COR388, is an orally-administered, brain-penetrating small molecule gingipain inhibitor.  ... More ...  



Risk Grade

Where does CRTX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 55.66
Open Date:
Jan. 27, 2020
Close Price:
$ 54.60
Close Date:
Jan. 27, 2020


Consensus Recommendation

Analyst Info